title: [A Retrospective Case Study of Combination Chemotherapy with Bevacizumab for Recurrent Ovarian Cancer].
abstract: OBJECTIVE
  Treatment for ovarian cancer with bevacizumab(Bmab)has been covered by public medical insurance in Japan since November 2013. It is recommended that the use of Bmab is limited to the first treatment for FIGO stage III or IV ovarian cancer. The OCEAN trial for platinum sensitivity in relapsed patients and the AURELIA trial for platinum-resistance in relapsed patients were performed, and both significantly improved progression-free survival.
  
  
  METHODS
  We retrospectively studied patients receiving Bmab with an anticancer agent for recurrent ovarian cancer. Written informed consent was obtained from all patients.
  
  
  RESULTS
  Between November 2013 and September 2015, Bmab at 15mg/kg/3-4 week was administered to 20 patients with recurrent ovarian cancer. The median age was 58 years(range 32-81)and the median performance status was 0-2. Platinum-sensitive recurrence occurred in 6 patients. The response rate and disease control rate of combination chemotherapy with Bmab was 50.0% and 57.1%. However, 11 patients stopped treatment with Bmab due to serious adverse events.
  
  
  CONCLUSIONS
  Combination chemotherapy with Bmab for recurrent ovarian cancer may be feasible.
authors.affiliation: Dept. of Gynecologic and Obstetrics, Kansai Rosai Hospital.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Hori
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Tsuruta
authors.forename: Chihiro
authors.initials: C
authors.lastname: Odani
authors.forename: Hitomi
authors.initials: H
authors.lastname: Ono
authors.forename: Rieko
authors.initials: R
authors.lastname: Ohkubo
authors.forename: Kanoko
authors.initials: K
authors.lastname: Shimoji
authors.forename: Junko
authors.initials: J
authors.lastname: Murakami
authors.forename: Mio
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Lina
authors.initials: L
authors.lastname: Tashima
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Ito
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab